MAIA Biotechnology, Inc. is a Chicago-based clinical stage biotechnology company with a focus on discovering and commercializing therapies for cancer, primarily non-small cell lung cancer. Its lead asset, THIO, combines two mechanisms of action, telomere targeting and immunogenicity, and is an investigational drug candidate. The company was established in 2018.